Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®

Eisai said Canada’s Drug Agency (CDA-AMC) issued a final recommendation for public reimbursement of Leqembi (lecanemab) for eligible patients with mild cognitive impairment/early-stage Alzheimer’s in Canada. The reimbursement nod is a meaningful commercialization step that should improve expected regional access and demand prospects for the therapy.